Universidad de Alcalá (UAH)

Developments and results in the context of the JEM-EUSO program obtained with the ESAF simulation and analysis framework (2023) Abe S, Adams JH, Allard D, Alldredge P, Anchordoqui L, Anzalone A, Arnone E, et al. Journal article CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2023) Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, et al. Journal article A Review of the EUSO-Balloon Pathfinder for the JEM-EUSO Program (2022) Adams JH, Ahmad S, Allard D, Anzalone A, Bacholle S, Barrillon P, Bayer J, et al. Journal article, Review article Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study (2022) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, et al. Journal article Quantum gravity phenomenology at the dawn of the multi-messenger era—A review (2022) Addazi A, Alvarez-Muniz J, Alves Batista R, Amelino-Camelia G, Antonelli V, Arzano M, Asorey M, et al. Journal article, Review article Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment (2021) Lamarca A, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel ME, Alonso-Gordoa T Journal article, Review article Odontoblast TRPC5 channels signal cold pain in teeth (2021) Bernal L, Sotelo-Hitschfeld P, König C, Sinica V, Wyatt A, Winter Z, Hein A, et al. Journal article PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution Fenchel Duality Theory and a Primal-Dual Algorithm on Riemannian Manifolds (2021) Bergmann R, Herzog R, Silva Louzeiro M, Tenbrinck D, Vidal-Núñez J Journal article Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2020) Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, et al. Conference contribution